Home Access and Saliva Diagnostics resolve lawsuits:
This article was originally published in Clinica
US companies Saliva Diagnostic Systems and Home Access Health have dropped legal proceedings against each other and negotiated a new contract. SDS will re-license Omni-Sal, a saliva collection device, to Illinois-based Home Access for non-rapid testing (see Clinica No 690, p 15). Under the terms of the deal, SDS will continue to sell and license Omni-Sal for rapid testing, non-HIV applications and non-rapid testing other than in kits. The dispute was settled after both companies agreed to mediation hearings in August.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.